United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 – 2028
Description
United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 – 2028
Amid the COVID-19 crisis, the United States human vaccines market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period.
The prominent factors that are expected to contribute to the growth of the United States human vaccines market:
Increased Disease Awareness
Approval/launches of the New Vaccines
Rising Focus on Immunization Programs
Increasing Investments and Government Support for the Vaccines Development
After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States human vaccines market are obtained with maximum precision.
This new 2022 market report provides a holistic analysis of the entire United States human vaccines market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States’ human vaccines market. The report also provides up–to–date historical market size data for the period 2018 – 2021 and an illustrative forecast to 2028 covering key market aspects like market value, analysis, and trends for human vaccines in the United States. A comprehensive analysis has been done on market share with the percentage of all the 45 human vaccines brand used in the United States.
The report contains a deep analysis of the United States human vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market. The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2021, and forecasts to 2028. The report also details the latest information about the vaccine’s pricing analysis, insights, and trends, and the regulatory framework of the United States human vaccines market.
The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, promising vaccines in the clinical development, and the newest developments
The report will serve as a source for a 360-degree analysis, thoroughly integrating different models.
This Newest and Comprehensive the United States Human Vaccines Market Research Report 2022 Delivers:
Comprehensive Research Methodology of the United States Human Vaccines Market
Detailed and Extensive Market Overview with Key Analyst Insights
Insights about Market Determinants that are Stimulating the United States Human Vaccines Market
To Analyze the Historical Growth in the Market Size of the United States Human Vaccines Market from 2018 to 2021
To Estimate and Forecast the Market Size of the United States Human Vaccines Market from 2022 to 2028 and Growth Rate until 2028
Detailed Insights of the Top 45 Human Vaccines Market Value Used in the U.S. with Six Years Forecast
An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate
Delivers All-inclusive Insights on the Latest Pricing Analysis, Insights, and Trends
Delivers an In-Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Human Vaccines Market
An Insightful Investigation has been done on Promising Human Vaccines in the Clinical Development
Delivers Comprehensive Insights into the Regulatory Framework of the United States Human Vaccines Market
Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement
A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Human Vaccines in the Clinical Development, and Present Development
The Key Market Players for the United States Human Vaccines Market are Listed Below:
Pfizer
Merck
Sanofi Pasteur
Seqirus (CSL Limited)
AstraZeneca
GlaxoSmithKline (GSK)
Emergent Biosolutions
Dynavax Technologies Corporation
The Following 45 Leading Human Vaccines Brand are Detailed with Market Value and Six-Years Forecast:
1) Fluad
2) Trumenba
3) Deptacel
4) Quadracel
5) Kinrix
6) Pentacel
7) Vaxelis
8) IPOL
9) Vaqta
10) Havrix
11) Twinrix
12) Engerix
13) PedvaxHIB
14) ActHIB
15) Hiberix
16) MenQuadfi
17) Tenivac
18) Imovax
19) Prevnar 13
20) Gardasil 9
21) Menactra
22) Fluarix
23) FluLaval
24) Varivax
25) Proquad
26) M–M–R II
27) Adacel
28) Boostrix
29) Bexsero
30) Menveo
31) Shingrix
32) Rotateq
33) Rotarix
34) Infanrix
35) Pediarix
36) Heplisav–B
37) TDVAX
38) Biothrax
39) Recombivax HB
40) Pneumovax 23
41) FluMist Quadrivalent
42) Flucelvax Quadrivalent
43) Afluria Quadrivalent
44) Fluzone Quadrivalent
45) Flublok Quadrivalent
The Report Helps Answer the Following Questions:
What is the current scenario of the United States human vaccines market?
What is the total market size and forecast (until 2028) of the United States human vaccines market?
How big is the United States human vaccines market?
At what CAGR is the U.S. human vaccines market projected to grow in the forecast period (2022-2028)?
What are the leading human vaccines? What are their revenue potentials to 2028?
Which human vaccine brand provides the highest market share?
What is the regulatory framework in the United States vaccines market?
What are the key factors driving the United States human vaccines market?
What are the key challenges of the United States human vaccines market?
What are the major deals and agreement happenings in the United States human vaccines market?
What are the United States human vaccines pricing trends and analysis?
What are the various human vaccines available in the United States?
Who are the topmost market players? What are their happenings, current developments, and scenarios?
How is the market predicted to develop in the future?
Amid the COVID-19 crisis, the United States human vaccines market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period.
The prominent factors that are expected to contribute to the growth of the United States human vaccines market:
Increased Disease Awareness
Approval/launches of the New Vaccines
Rising Focus on Immunization Programs
Increasing Investments and Government Support for the Vaccines Development
After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States human vaccines market are obtained with maximum precision.
This new 2022 market report provides a holistic analysis of the entire United States human vaccines market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States’ human vaccines market. The report also provides up–to–date historical market size data for the period 2018 – 2021 and an illustrative forecast to 2028 covering key market aspects like market value, analysis, and trends for human vaccines in the United States. A comprehensive analysis has been done on market share with the percentage of all the 45 human vaccines brand used in the United States.
The report contains a deep analysis of the United States human vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market. The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2021, and forecasts to 2028. The report also details the latest information about the vaccine’s pricing analysis, insights, and trends, and the regulatory framework of the United States human vaccines market.
The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, promising vaccines in the clinical development, and the newest developments
The report will serve as a source for a 360-degree analysis, thoroughly integrating different models.
This Newest and Comprehensive the United States Human Vaccines Market Research Report 2022 Delivers:
Comprehensive Research Methodology of the United States Human Vaccines Market
Detailed and Extensive Market Overview with Key Analyst Insights
Insights about Market Determinants that are Stimulating the United States Human Vaccines Market
To Analyze the Historical Growth in the Market Size of the United States Human Vaccines Market from 2018 to 2021
To Estimate and Forecast the Market Size of the United States Human Vaccines Market from 2022 to 2028 and Growth Rate until 2028
Detailed Insights of the Top 45 Human Vaccines Market Value Used in the U.S. with Six Years Forecast
An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate
Delivers All-inclusive Insights on the Latest Pricing Analysis, Insights, and Trends
Delivers an In-Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Human Vaccines Market
An Insightful Investigation has been done on Promising Human Vaccines in the Clinical Development
Delivers Comprehensive Insights into the Regulatory Framework of the United States Human Vaccines Market
Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement
A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Human Vaccines in the Clinical Development, and Present Development
The Key Market Players for the United States Human Vaccines Market are Listed Below:
Pfizer
Merck
Sanofi Pasteur
Seqirus (CSL Limited)
AstraZeneca
GlaxoSmithKline (GSK)
Emergent Biosolutions
Dynavax Technologies Corporation
The Following 45 Leading Human Vaccines Brand are Detailed with Market Value and Six-Years Forecast:
1) Fluad
2) Trumenba
3) Deptacel
4) Quadracel
5) Kinrix
6) Pentacel
7) Vaxelis
8) IPOL
9) Vaqta
10) Havrix
11) Twinrix
12) Engerix
13) PedvaxHIB
14) ActHIB
15) Hiberix
16) MenQuadfi
17) Tenivac
18) Imovax
19) Prevnar 13
20) Gardasil 9
21) Menactra
22) Fluarix
23) FluLaval
24) Varivax
25) Proquad
26) M–M–R II
27) Adacel
28) Boostrix
29) Bexsero
30) Menveo
31) Shingrix
32) Rotateq
33) Rotarix
34) Infanrix
35) Pediarix
36) Heplisav–B
37) TDVAX
38) Biothrax
39) Recombivax HB
40) Pneumovax 23
41) FluMist Quadrivalent
42) Flucelvax Quadrivalent
43) Afluria Quadrivalent
44) Fluzone Quadrivalent
45) Flublok Quadrivalent
The Report Helps Answer the Following Questions:
What is the current scenario of the United States human vaccines market?
What is the total market size and forecast (until 2028) of the United States human vaccines market?
How big is the United States human vaccines market?
At what CAGR is the U.S. human vaccines market projected to grow in the forecast period (2022-2028)?
What are the leading human vaccines? What are their revenue potentials to 2028?
Which human vaccine brand provides the highest market share?
What is the regulatory framework in the United States vaccines market?
What are the key factors driving the United States human vaccines market?
What are the key challenges of the United States human vaccines market?
What are the major deals and agreement happenings in the United States human vaccines market?
What are the United States human vaccines pricing trends and analysis?
What are the various human vaccines available in the United States?
Who are the topmost market players? What are their happenings, current developments, and scenarios?
How is the market predicted to develop in the future?
Table of Contents
215 Pages
- 1. Executive Summary
- 2. United States Human Vaccines Market Size and Forecast (2018 – 2028)
- 3. United States Human Vaccines Brand Market Share and Y–o–Y Growth (%), 2018 – 2028
- 4. Key Market Growth Drivers and Challenges in the United States Human Vaccines Market
- 4.1 Key Market Growth Drivers
- 4.2 Key Market Challenges
- 5. United States Top 45 Human Vaccines Market Value Analysis, Insights and Forecasts,2018 – 2028
- 5.1 Daptacel
- 5.2 Quadracel
- 5.3 Kinrix
- 5.4 Vaxelis
- 5.5 IPOL
- 5.6 Vaqta
- 5.7 Havrix
- 5.8 Twinrix
- 5.9 Engerix B
- 5.10 PedvaxHIB
- 5.11 ActHIB
- 5.12 Hiberix
- 5.13 MenQuadfi
- 5.14 Tenivac
- 5.15 Imovax
- 5.16 FluMist Quadrivalent
- 5.17 Prevnar 13
- 5.18 Gardasil 9
- 5.19 Fluzone Quadrivalent
- 5.20 Flublok
- 5.21 Flucelvax Quadrivalent
- 5.22 Afluria Quadrivalent
- 5.23 Fluad
- 5.24 Varivax
- 5.25 Menactra
- 5.26 Proquad
- 5.27 Pneumovax 23
- 5.28 Fluarix
- 5.29 FluLaval
- 5.30 M–M–R II
- 5.31 Adacel
- 5.32 Boostrix
- 5.33 Bexsero
- 5.34 Menveo
- 5.35 Trumenba
- 5.36 Shingrix
- 5.37 Pentacel
- 5.38 Recombivax HB
- 5.39 Rotateq
- 5.40 Rotarix
- 5.41 Pediarix
- 5.42 Infanrix
- 5.43 Heplisav–B
- 5.44 TDVAX
- 5.45 BioThrax
- 5.46 Other Vaccines
- 6. United States Human Vaccines Pricing Analysis, Insights and Trends
- 7. Regulatory Framework of the United States Human Vaccines Market
- 8. Major Deals and Agreement Happenings in the Human Vaccines Market
- 8.1 Merger & Acquisitions
- 8.2 Collaboration Deals
- 8.3 Licensing Agreement
- 8.4 Exclusive Agreement
- 8.5 Distribution Agreement
- 8.6 Partnership Deals
- 9. Leading Companies in the United States Human Vaccines Market
- 9.1 Sanofi Pasteur
- 9.1.1 Business Overview
- 9.1.2 Human Vaccines Portfolio
- 9.1.3 Promising Human Vaccines in the Clinical Development
- 9.1.4 Recent Development
- 9.2 GlaxoSmithKline (GSK)
- 9.2.1 Business Overview
- 9.2.2 Human Vaccines Portfolio
- 9.2.3 Promising Human Vaccines in the Clinical Development
- 9.2.4 Recent Development
- 9.3 Merck
- 9.3.1 Business Overview
- 9.3.2 Human Vaccines Portfolio
- 9.3.3 Promising Human Vaccines in the Clinical Development
- 9.3.4 Recent Development
- 9.4 Pfizer
- 9.4.1 Business Overview
- 9.4.2 Human Vaccines Portfolio
- 9.4.3 Promising Human Vaccines in the Clinical Development
- 9.4.4 Recent Development
- 9.5 Seqirus (CSL Limited)
- 9.5.1 Business Overview
- 9.5.2 Human Vaccines Portfolio
- 9.5.3 Promising Human Vaccines in the Clinical Development
- 9.5.4 Recent Development
- 9.6 AstraZeneca
- 9.6.1 Business Overview
- 9.6.2 Human Vaccines Portfolio
- 9.6.3 Promising Human Vaccines in the Clinical Development
- 9.6.4 Recent Development
- 9.7 Dynavax Technologies Corporation
- 9.7.1 Business Overview
- 9.7.2 Human Vaccines Portfolio
- 9.7.3 Promising Human Vaccines in the Clinical Development
- 9.7.4 Recent Development
- 9.8 Emergent BioSolutions Inc.
- 9.8.1 Business Overview
- 9.8.2 Human Vaccines Portfolio
- 9.8.3 Promising Human Vaccines in the Clinical Development
- 9.8.4 Recent Development
- List of Tables
- Table 3–1: United States Human Vaccines Brand Market Share & Y–o–Y Growth (Percent), 2018 – 2021
- Table 3–2: United States Human Vaccines Brand Market Share & Y–o–Y Growth Forecast (Percent), 2022 – 2028
- Table 6–1: United States Adult Vaccines Price, 2022 – 2023
- Table 6–2: United States Adult Influenza Vaccines Price, 2022 – 2023
- Table 6–3: United States Pediatric Vaccines Price, 2022 – 2023
- Table 6–4: United States Pediatric Influenza Vaccines Price, 2022 – 2023
- Table 7–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
- Table 8–1: Merger & Acquisitions in the Human Vaccines Market
- Table 8–2: Collaboration Deals in the Human Vaccines Market
- Table 8–3: Licensing Agreement in the Human Vaccines Market
- Table 8–4: Exclusive Agreement in the Human Vaccines Market
- Table 8–5: Distribution Agreement in the Human Vaccines Market
- Table 8–6: Partnership Deals in the Human Vaccines Market
- Table 9–1: Sanofi Promising Human Vaccines in the Clinical Development
- Table 9–2: GSK Promising Human Vaccines in the Clinical Development
- Table 9–3: Merck Promising Human Vaccines in the Clinical Development
- Table 9–4: Pfizer Promising Human Vaccines in the Clinical Development
- Table 9–5: Seqirus Promising Human Vaccines in the Clinical Development
- Table 9–6: AstraZeneca Promising Human Vaccines in the Clinical Development
- Table 9–7: Dynavax Technologies Corporation Promising Human Vaccines in the Clinical Development
- Table 9–8: Emergent BioSolutions Inc. Promising Human Vaccines in the Clinical Development
- List of Figures
- Figure 2–1: United States Human Vaccines Market Size (Million US$),2018 – 2021
- Figure 2–2: United States Human Vaccines Market Size Forecast (Million US$),2022 – 2028
- Figure 5–1: United States Daptacel Market Value (Million US$),2018 – 2021
- Figure 5–2: United States Daptacel Market Value Forecast (Million US$),2022 – 2028
- Figure 5–3: United States Quadracel Market Value (Million US$),2018 – 2021
- Figure 5–4: United States Quadracel Market Value Forecast (Million US$),2022 – 2028
- Figure 5–5: United States Kinrix Market Value (Million US$),2018 – 2021
- Figure 5–6: United States Kinrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–7: United States Vaxelis Market Value (Million US$),2018 – 2021
- Figure 5–8: United States Vaxelis Market Value Forecast (Million US$),2022 – 2028
- Figure 5–9: United States IPOL Market Value (Million US$),2018 – 2021
- Figure 5–10: United States IPOL Market Value Forecast (Million US$),2022 – 2028
- Figure 5–11: United States Vaqta Market Value (Million US$),2018 – 2021
- Figure 5–12: United States Vaqta Market Value Forecast (Million US$),2022 – 2028
- Figure 5–13: United States Havrix Market Value (Million US$),2018 – 2021
- Figure 5–14: United States Havrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–15: United States Twinrix Market Value (Million US$),2018 – 2021
- Figure 5–16: United States Twinrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–17: United States Engerix B Market Value (Million US$),2018 – 2021
- Figure 5–18: United States Engerix B Market Value Forecast (Million US$),2022 – 2028
- Figure 5–19: United States PedvaxHIB Market Value (Million US$),2018 – 2021
- Figure 5–20: United States PedvaxHIB Market Value Forecast (Million US$),2022 – 2028
- Figure 5–21: United States ActHIB Market Value (Million US$),2018 – 2021
- Figure 5–22: United States ActHIB Market Value Forecast (Million US$),2022 – 2028
- Figure 5–23: United States Hiberix Market Value (Million US$),2018 – 2021
- Figure 5–24: United States Hiberix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–25: United States MenQuadfi Market Value and Forecast (Million US$),2021 – 2028
- Figure 5–26: United States Tenivac Market Value (Million US$),2018 – 2021
- Figure 5–27: United States Tenivac Market Value Forecast (Million US$),2022 – 2028
- Figure 5–28: United States Imovax Market Value (Million US$),2018 – 2021
- Figure 5–29: United States Imovax Market Value Forecast (Million US$),2022 – 2028
- Figure 5–30: United States FluMist Quadrivalent Market Value (Million US$),2018 – 2021
- Figure 5–31: United States FluMist Quadrivalent Market Value Forecast (Million US$),2022 – 2028
- Figure 5–32: United States Prevnar 13 Market Value (Million US$),2018 – 2021
- Figure 5–33: United States Prevnar 13 Market Value Forecast (Million US$),2022 – 2028
- Figure 5–34: United States Gardasil 9 Market Value (Million US$),2018 – 2021
- Figure 5–35: United States Gardasil 9 Market Value Forecast (Million US$),2022 – 2028
- Figure 5–36: United States Fluzone Market Value (Million US$),2018 – 2021
- Figure 5–37: United States Fluzone Market Value Forecast (Million US$),2022 – 2028
- Figure 5–38: United States Flublok Market Value (Million US$), 2018 – 2021
- Figure 5–39: United States Flublok Market Value Forecast (Million US$), 2022 – 2028
- Figure 5–40: United States Flucelvax Quadrivalent Market Value (Million US$),2018 – 2021
- Figure 5–41: United States Flucelvax Quadrivalent Market Value Forecast (Million US$),2022 – 2028
- Figure 5–42: United States Afluria Quadrivalent Market Value (Million US$),2018 – 2021
- Figure 5–43: United States Afluria Quadrivalent Market Value Forecast (Million US$),2022 – 2028
- Figure 5–44: United States Fluad Market Value (Million US$),2018 – 2021
- Figure 5–45: United States Fluad Market Value Forecast (Million US$),2022 – 2028
- Figure 5–46: United States Varivax Market Value (Million US$),2018 – 2021
- Figure 5–47: United States Varivax Market Value Forecast (Million US$),2022 – 2028
- Figure 5–48: United States Menactra Market Value (Million US$),2018 – 2021
- Figure 5–49: United States Menactra Market Value Forecast (Million US$),2022 – 2028
- Figure 5–50: United States Proquad Market Value (Million US$),2018 – 2021
- Figure 5–51: United States Proquad Market Value Forecast (Million US$),2022 – 2028
- Figure 5–52: United States Pneumovax 23 Market Value (Million US$),2018 – 2021
- Figure 5–53: United States Pneumovax 23 Market Value Forecast (Million US$),2022 – 2028
- Figure 5–54: United States Fluarix Market Value (Million US$),2018 – 2021
- Figure 5–55: United States FluLaval Market Value Forecast (Million US$),2022 – 2028
- Figure 5–56: United States FluLaval Market Value (Million US$),2018 – 2021
- Figure 5–57: United States FluLaval Market Value Forecast (Million US$),2022 – 2028
- Figure 5–58: United States M–M–R ll Market Value (Million US$),2018 – 2021
- Figure 5–59: United States M–M–R ll Market Value Forecast (Million US$),2022 – 2028
- Figure 5–60: United States Adacel Market Value (Million US$),2018 – 2021
- Figure 5–61: United States Adacel Market Value Forecast (Million US$),2022 – 2028
- Figure 5–62: United States Boostrix Market Value (Million US$),2018 – 2021
- Figure 5–63: United States Boostrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–64: United States Bexsero Market Value (Million US$),2018 – 2021
- Figure 5–65: United States Bexsero Market Value Forecast (Million US$),2022 – 2028
- Figure 5–66: United States Menveo Market Value (Million US$),2018 – 2021
- Figure 5–67: United States Menveo Market Value Forecast (Million US$),2022 – 2028
- Figure 5–68: United States Trumenba Market Value (Million US$),2018 – 2021
- Figure 5–69: United States Trumenba Market Value Forecast (Million US$),2022 – 2028
- Figure 5–70: United States Shingrix Market Value (Million US$),2018 – 2021
- Figure 5–71: United States Shingrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–72: United States Pentacel Market Value (Million US$),2018 – 2021
- Figure 5–73: United States Pentacel Market Value Forecast (Million US$),2022 – 2028
- Figure 5–74: United States Recombivax HB Market Value (Million US$),2018 – 2021
- Figure 5–75: United States Recombivax HB Market Value Forecast (Million US$),2022 – 2028
- Figure 5–76: United States Rotateq Market Value (Million US$),2018 – 2021
- Figure 5–77: United States Rotateq Market Value Forecast (Million US$),2022 – 2028
- Figure 5–78: United States Rotarix Market Value (Million US$),2018 – 2021
- Figure 5–79: United States Rotarix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–80: United States Pediarix Market Value (Million US$),2018 – 2021
- Figure 5–81: United States Pediarix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–82: United States Infanrix Market Value (Million US$),2018 – 2021
- Figure 5–83: United States Infanrix Market Value Forecast (Million US$),2022 – 2028
- Figure 5–84: United States Heplisav–B Market Value (Million US$),2018 – 2021
- Figure 5–85: United States Heplisav–B Market Value Forecast (Million US$),2022 – 2028
- Figure 5–86: United States TDVAX Market Value (Million US$),2018 – 2021
- Figure 5–87: United States TDVAX Market Value Forecast (Million US$),2022 – 2028
- Figure 5–88: United States BioThrax Market Value (Million US$),2018 – 2021
- Figure 5–89: United States BioThrax Market Value Forecast (Million US$),2022 – 2028
- Figure 5–90: United States Other Human Vaccines Market Value (Million US$),2018 – 2021
- Figure 5–91: United States Other Human Vaccines Market Value Forecast (Million US$),2022 – 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.